Accession Number:



Targeted Lung-Derived Proteins as a Therapeutic Strategy Against Breast Cancer Metastasis

Descriptive Note:

Technical Report,15 Aug 2018,14 Aug 2019

Corporate Author:

The University of Western Ontario London Canada

Personal Author(s):

Report Date:


Pagination or Media Count:



Therapy for lung metastasis is often given systemically, causing significant toxicity. However, the lung holds potential for direct targeting via inhaled drugs an approach that has shown promise in treating respiratory diseases but remains underexplored in oncology. This project is testing the hypothesis that CD44-interacting proteins produced in the lung promote breast cancer metastasis and can be targeted directly using inhalable drug delivery. To date, the major findings for the project are that theCD44-interactiing proteins OPN, FGF2, and EPL selectins have complementary and important roles in mediating breast cancer metastatic behavior in response to the lung microenvironment. OPN and selectins were found to be necessary for metastatic colonization of the lung, particularly for more aggressive breast cancer cell lines. The pan-selectin antagonist bimosiamose has been chosen to move forward into drug formulation and pre-clinical testing as an inhalable treatment for lung metastasis of breast cancer. Drug formulation and optimization studies are progressing well in preparation for the in vivo pre-clinical therapeutic studies which will be carried out in the final year of the award.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: